Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure and Iron Deficiency in Romania

1. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012;21:365-371. doi: 10.1016/j.carpath.2011.11.007.10.1016/j.carpath.2011.11.00722227365Open DOISearch in Google Scholar

2. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime Risk for Developing Congestive Heart Failure. Circulation. 2002;106:3068-3072. doi: 10.1161/01.CIR.0000039105.49749.6F.10.1161/01.CIR.0000039105.49749.6Open DOISearch in Google Scholar

3. Bredy C, Ministeri M, Kempny A, et al. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome. Eur Heart J Qual Care Clin Outcomes. 2018;4:51-58. doi: 10.1093/ehjqcco/qcx031.10.1093/ehjqcco/qcx03128950356Open DOISearch in Google Scholar

4. Chioncel O, Tatu-Chitoiu G, Christodorescu R, et al. Characteristics of patients with heart failure from Romania enrolled in - ESC-HF Long-Term (ESC-HF-LT) Registry. Romanian Journal of Cardiology. 2015;25:413-420.Search in Google Scholar

5. Sinescu C, Axente L. Heart failure – concepts and significance. Birth of a prognostic model. J Med Life. 2010;3:421-429.Search in Google Scholar

6. Pop D, Penciu OM, Sitar-Taut AV, Zdrenghea DT. Comparative heart failure profile over a 3-year period in a Romanian general hospital. Clin Interv Aging. 2013;8:999-1005. doi: 10.2147/CIA.S46760.10.2147/CIA.S46760373387323930074Search in Google Scholar

7. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am Heart J. 2013;165:575-82.e3. doi: 10.1016/j.ahj.2013.01.017.10.1016/j.ahj.2013.01.01723537975Open DOISearch in Google Scholar

8. Cleland JGF, Zhang J, Pellicori P, et al. Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure. JAMA Cardiol. 2016;1:539-547. doi: 10.1001/jamacardio.2016.1161.10.1001/jamacardio.2016.116127439011Search in Google Scholar

9. Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58:1241-1251. doi: 10.1016/j.jacc.2011.04.040.10.1016/j.jacc.2011.04.04021903058Open DOISearch in Google Scholar

10. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31:1872-1880. doi: 10.1093/eurheartj/ehq158.10.1093/eurheartj/ehq15820570952Search in Google Scholar

11. Comín-Colet J, Enjuanes C, González G, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail. 2013;15:1164-1172. doi: 10.1093/eurjhf/hft083.10.1093/eurjhf/hft083378214623703106Open DOISearch in Google Scholar

12. Dalal J, Katekhaye V, Jain R. Effect of ferric carboxymaltose on hospitalization and mortality outcomes in chronic heart failure: A meta-analysis. Indian Heart J. 2017;69:736-741. doi: 10.1016/j.ihj.2017.10.009.10.1016/j.ihj.2017.10.009571730029174251Open DOISearch in Google Scholar

13. Anker SD, Comín-Colet J, Filippatos G, et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med. 2009;361:2436-2448. doi: 10.1056/NEJMoa0908355.10.1056/NEJMoa090835519920054Open DOISearch in Google Scholar

14. Ponikowski P, van Veldhuisen DJ, Comín-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657-668. doi: 10.1093/eurheartj/ehu385.10.1093/eurheartj/ehu385435935925176939Open DOISearch in Google Scholar

15. Hotărârea de Guvern nr. Nr. 140/2018 din 21 martie 2018 publicată în Monitorul Oficial al României Partea I, nr. 270 din 27 martie 2018. Available at: http://www.casan.ro/casalba/media/postFiles/HG%20140-CONTRACT%20CADRU%202018-2019.pdfSearch in Google Scholar

16. Ordinul ministrului sănătății și al președintelui Casei Naționale de Asigurări de Sănătate nr. 397/836/2018 privind aprobarea Normelor metodologice de aplicare în anul 2018 a Hotărârii Guvernului nr. 140/2018 pentru aprobarea pachetelor de servicii și a Contractului-cadru care reglementează condițiile acordării asistenței medicale, a medicamentelor și a dispozitivelor medicale în cadrul sistemului de asigurări sociale de sănătate pentru anii 2018-2019. Available at: http://www.cnas.ro/casgorj/media/postFiles/Ordin%20397-836_2018%20(actualizat%20cu%20Ordin%20MS-CNAS%20910-1161_2018).pdfSearch in Google Scholar

17. Theidel U, Väätäinen S, Martikainen J, Soini E, Hardt T, Doehner W. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC heart failure. 2017;4:274-281. doi: 10.1002/ehf2.12179.10.1002/ehf2.12179554273128772041Open DOISearch in Google Scholar

18. Bourguignon S, Faller M, Champs F-O, et al. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC Heart Fail. 2019;6:559-569. doi: 10.1002/ehf2.12432.10.1002/ehf2.12432648771731021531Open DOISearch in Google Scholar

19. Ressl S, Walter E, Bauer M. Budget-Impact-Analysis Of Iron Treatment Using Intravenous Ferric Carboxymaltose In Patients With Chronic Heart Failure And Iron Deficiency In Austria. Value Health. 2015;18:A384. doi: 10.1016/j.jval.2015.09.831.10.1016/j.jval.2015.09.831Open DOISearch in Google Scholar

20. Walter E, Bauer M, Ressl S. Cost-Effectiveness Of Ferric Carboxymaltose In Patients With Iron Deficiency And Chronic Heart Failure In Austria. Value Health. 2015;18:A392. doi: 10.1016/j.jval.2015.09.876.10.1016/j.jval.2015.09.876Open DOISearch in Google Scholar

21. Gutzwiller FS, Schwenkglenks M, Blank PR, et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur J Heart Fail. 2012;14:782-790. doi: 10.1093/eurjhf/hfs083.10.1093/eurjhf/hfs083338054622689292Open DOISearch in Google Scholar

22. Comín-Colet J, Rubio-Rodríguez D, Rubio-Terrés C, et al. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. Rev Esp Cardiol (Engl Ed). 2015;68:846-851. doi: 10.1016/j.rec.2014.10.010.10.1016/j.rec.2014.10.01025649970Open DOISearch in Google Scholar

23. Hofmarcher T, Borg S. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. J Med Econ. 2015;18:492-501. doi: 10.3111/13696998.2015.1029491.10.3111/13696998.2015.102949125766863Open DOISearch in Google Scholar

24. Mylonas C, Kourlaba G, Berberian K, Maniadakis N. Economic Evaluation Of Ferric Carboxymaltose In Patients With Chronic Heart Failure And Iron Deficiency: An Analysis For Greece Based On Fair-Hf Trial. Value Health. 2014;17:A486. doi: 10.1016/j.jval.2014.08.1424.10.1016/j.jval.2014.08.142427201432Open DOISearch in Google Scholar

25. Lim EA, Sohn HS, Lee H, Choi SE. Cost-utility of ferric carboxymaltose (Ferinject^®) for iron-deficiency anemia patients with chronic heart failure in South Korea. Cost effectiveness and resource allocation: C/E. 2014;12:19. doi: 10.1186/1478-7547-12-19.10.1186/1478-7547-12-19416657425278814Open DOISearch in Google Scholar

26. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200. doi: 10.1002/ejhf.592.10.1002/ejhf.59227207191Open DOISearch in Google Scholar